Health Ministry proposes central oversight for antimicrobials, bulk drug licensing reform
Synopsis
Key Takeaways
India's Health Ministry on Thursday, 19 November 2026, proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, that would place antimicrobial products under Central Licensing Authority (CLA) oversight — a move aimed at tightening quality controls and curbing the spread of antimicrobial resistance (AMR). A separate proposal to reform bulk drug licensing was announced alongside, targeting gaps in India's pharmaceutical supply chain.
Why Central Oversight for Antimicrobials
The ministry cited concerns that manufacturing licences for antimicrobial products were being granted by state authorities without adequate regulatory scrutiny — specifically, without the bioavailability, bioequivalence, and stability studies typically required for new drugs. According to an official statement, the absence of these assessments risks compromising the quality, safety, and efficacy of antimicrobials.
The statement warned that substandard or ineffective antimicrobials can accelerate the development and spread of antimicrobial resistance, a recognised threat to patient safety. India is among the world's largest consumers and producers of antibiotics, making robust regulatory oversight a matter of public health urgency.
What the Proposed Amendment Would Change
Under the proposed framework, manufacturers would be required to secure permission from the Central Licensing Authority before applying for a manufacturing licence from the relevant State Licensing Authority (SLA). This two-step clearance would effectively bring antimicrobials within the same regulatory bracket as new drugs under the 2019 Rules.
'Accordingly, manufacturers would be required to obtain permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA). This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products,' the ministry's statement read.
The draft notification has been published to invite objections and suggestions from stakeholders and members of the public before the amendment is considered for finalisation by the Central Government.
Bulk Drug Licensing: Closing a Supply Chain Gap
In a parallel proposal, the ministry has moved to amend the Drugs Rules, 1945, to introduce a separate application form and licence form for the wholesale sale of bulk drugs — covering both active and inactive bulk substances. At present, a single common licence covers wholesale sales of both formulations and bulk drugs, a conflation the ministry now considers insufficient for effective oversight.
The new dedicated licensing framework would require wholesalers to declare the categories of bulk drugs they handle, including those covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Critically, the sale of bulk drugs would be conducted under the personal supervision of a competent person, strengthening accountability across the distribution chain.
Significance and What Comes Next
Together, these two proposals represent a meaningful tightening of India's pharmaceutical regulatory architecture at a time when the country faces pressure — both domestically and from international partners — to demonstrate higher standards in drug manufacturing. Notably, India's pharmaceutical sector has faced recurring scrutiny over quality lapses in recent years, and the AMR threat is increasingly a global diplomatic priority.
Stakeholders and citizens have an opportunity to submit objections or suggestions before the amendments are finalised. The timeline for finalisation has not been specified, but the dual notification signals the ministry's intent to move on both fronts simultaneously. How quickly the Central Government converts these proposals into enforceable rules will be watched closely by industry and public health advocates alike.